Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 20

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Bladder transitional cell carcinoma stage I

Not yet recruiting

Efficacy of Enfortumab Vedotin plus Pembrolizumab in Adult Patients with Muscle‑Invasive Bladder Cancer Using a Bladder‑Sparing Response‑Adapted Approach

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Phenylketonuria

Not yet recruiting

A Phase 2 Study of MZE782 Safety, Tolerability, and Efficacy in Adults with Phenylketonuria

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Maze Therapeutics Inc.

Clear cell renal cell carcinoma+2

Not yet recruiting

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Clear cell papillary renal cell carcinoma

Not yet recruiting

Study of Sacituzumab Tirumotecan in Patients with Papillary Renal Cell Carcinoma and Variant Histology Urothelial Carcinoma (Rare Genitourinary Tumors)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Tirumotecan

Transitional cell carcinoma+1

Not yet recruiting

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Summit Therapeutics Inc.

Bladder cancer+2

Not yet recruiting

Long-Term Safety and Efficacy of aUroCell-Tx in Muscle-Invasive Bladder Cancer Patients Undergoing Neobladder Reconstruction – Extension Study

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:AUROCELL-TX
  • Sponsor:Phosprint S.A.

End stage renal disease+1

Not yet recruiting

Safety and efficacy of locally administered APAC, heparin sodium and sodium chloride to promote arteriovenous fistula maturation in patients with end‑stage kidney disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

Bladder cancer

Not yet recruiting

Long‑Term Follow‑Up of Mitomycin (UGN‑103) Treatment in Patients with Recurrent Low‑Grade Intermediate‑Risk Non‑Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Colon cancer+3

Not yet recruiting

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Abemaciclib
  • Sponsor:Institut Gustave Roussy

Metastatic renal cell carcinoma

Not yet recruiting

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Clear cell renal cell carcinoma

Not yet recruiting

Phase I study of 161Tb-PSMA-1 therapy and gallium‑68 gozetotide imaging in adult patients with metastatic clear cell renal cell carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Centre Leon Berard

Sepsis+3

Not yet recruiting

Comparison of ampicillin plus gentamicin versus piperacillin/tazobactam for empirical treatment of hospitalized patients with community‑acquired infection

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Region Hovedstaden

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.